Companies › Step Pharma, SAS
1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| STP938 (Dencatistat) | – | Phase 2 | Essential Thrombocythaemia; Solid Tumor; Lymphoma, B-Cell | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06297525 | STP938 (Dencatistat) | Phase 1 | Solid Tumor | Oncology | Dec 2026 |
| NCT05463263 | STP938 (Dencatistat) | Phase 1 | Lymphoma, B-Cell | Oncology | Dec 2026 |
| NCT06786234 | STP938 (Dencatistat) | Phase 2 | Essential Thrombocythaemia | Oncology | Jun 2028 |
No annotated target.
–
Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.